| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d93eee70e1b36f13cc71fbf1737adb08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99f5741a1adaef179e9a512599aaed95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e59b927ef09c3f125c969c74a6b29c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2014-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7157561ff7c84ffbfe01423b5c521873
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e29d447df77ef492a91ef38296a11258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_799076c1bfcbc1107209494fbf29b98e |
| publicationDate |
2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014184734-A1 |
| titleOfInvention |
Markers associated with mtor inhibition |
| abstract |
The present invention relates to methods for predicting sensitivity of a cancer patient for treatment with an mTOR inhibitor wherein minimal genetic alterations in the PI3K pathway and FGFR pathways and CCND1 are indicative of a higher benefit from mTOR therapy. |
| priorityDate |
2013-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |